Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

NCT02656706 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilumumab
DRUG: Nivolumab

Sponsor

Brown University

Collaborators

[object Object]
[object Object]